Salarius Pharmaceuticals Debt to Equity

As of the most recent data, SLRX shows a debt-to-equity ratio of 0.69. That is above the Healthcare sector average of 0.27. Scroll down for historical charts and peer comparison views.

The Healthcare sector average debt-to-equity ratio is about 0.27. Salarius Pharmaceuticals is at 0.69, which is higher that average. That is roughly 161.5% above the sector mean. Use the comparison chart on this page to see how SLRX stacks up against individual peers as well.

Investors watch SLRX's debt-to-equity ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Salarius Pharmaceuticals's latest reading is 0.69. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.

Besides this debt-to-equity ratio page, Stockcircle has Salarius Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect debt-to-equity ratio (currently 0.69) with ownership activity and broader fundamentals.

The Healthcare average debt-to-equity ratio is about 0.27, while SLRX is at 0.69. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.